Puma Biotechnology Inc. buy DerAlmanach100000
Start price
30.07.25
/
50%
€2.80
Target price
30.07.28
-
Performance (%)
22.50%
End price
11.08.25
€3.43
Summary
This prediction ended on 11.08.25 with a price of €3.43. The prediction had a final performance of 22.50%. DerAlmanach100000 has 50% into this predictionPuma Biotechnology is a publicly traded biopharmaceutical company that develops innovative cancer therapies targeting the most aggressive and difficult-to-treat forms of the disease. Puma's lead product is Nerlynx, an oral medication approved for the treatment of HER2-positive breast cancer, and the company also has a number of other promising drugs in its pipeline. Founded in 2010, Puma is headquartered in Los Angeles, California, and its shares trade on the NASDAQ exchange under the ticker symbol PBYI.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Puma Biotechnology Inc. | 12.241% | 12.241% |
| iShares Core DAX® | 0.734% | -0.964% |
| iShares Nasdaq 100 | -2.686% | -2.409% |
| iShares Nikkei 225® | -2.261% | -4.038% |
| iShares S&P 500 | -1.346% | -1.510% |
According to DerAlmanach100000 what are the pros and cons of Puma Biotechnology Inc. for the foreseeable future?
Pros
Very Future proof/growth oriented business model